Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Barr Fluoxetine Will Have Two Months Exclusivity Under "Worst Case"

Executive Summary

Barr believes that in a worst case scenario it will still have two months of Waxman/Hatch exclusivity for its generic version of Prozac (fluoxetine).

You may also be interested in...



Glucophage Generics Coming Soon, Bristol Says; Exclusivity Bill Clears Senate

Bristol-Myers Squibb expects the pediatric exclusivity reauthorization bill to be signed into law by the end of the month

Glucophage Generics Coming Soon, Bristol Says; Exclusivity Bill Clears Senate

Bristol-Myers Squibb expects the pediatric exclusivity reauthorization bill to be signed into law by the end of the month

Barr Fluoxetine Goal: 80% Generic Penetration In First Six Months

Barr hopes to achieve 80% generic substitution for Lilly's Prozac within the first six months after launch of its generic 20 mg fluoxetine capsules.

Related Content

UsernamePublicRestriction

Register

PS037459

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel